🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of XB010 in Subjects With Solid Tumors

RecruitingPhase 1Ages 18 Years - anyAllExelixis
NCT06545331 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
* Age 18 years or older on the day of consent. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. * Adequate organ and marrow function. * Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent. * The Cohort Expansion stage will enroll subjects with multiple tumor types (non-small cell lung cancer, hormone-receptor-positive breast cancer, head and neck cancer, esophageal squamous cell, triple-negative breast cancer). * Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.
💊

What it tests

  • XB010
  • Pembrolizumab
📍

Where

20 sites
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, United States
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, United States
Georgetown University Medical Center
Washington D.C., United States
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, United States
Winship Cancer Institute
Atlanta, United States
University of Chicago Medical Center
Chicago, United States
Siteman Cancer Center
St Louis, United States
Montefiore Medical Center - Montefiore Medical Park
The Bronx, United States

…and 12 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy